Hutchmed (China) (00013) rose by more than 5%, as of press time, up 5.11% to HKD 29.85, with a turnover of HKD 33.2161 million.
According to the Zhixin Financial APP, Hutchmed (China) (00013) rose by more than 5%, up 5.11% to HKD 29.85, with a turnover of HKD 33.2161 million.
On the news front, on June 7th, Hutchmed (China) announced the launch of a Phase I clinical trial of HMPL-506 for the treatment of hematological malignancies in China. The first patient received first-line treatment on May 31st. This study is a multicenter, open-label, Phase I clinical trial designed to evaluate the safety, pharmacokinetics, and efficacy of HMPL-506 for the treatment of hematologic malignancies. The study will be conducted in two stages, dose escalation and dose expansion, with plans to include at least 60 patients.
Hutchmed (China) previously stated that the results of the FRUTIGA China III Phase study using fluorouracil and paclitaxel in second-line treatment of advanced gastric cancer were published in Nature Medicine. The results of the study indicate that fluorouracil may become a new and effective treatment option for gastric cancer patients.